THC vs CBD vs CBG vs CBN vs THCV: The Real Differences Explained

Clinical Bottom Line: THC, CBD, CBG, CBN, and THCV are five distinct cannabinoids with different receptor targets, effects, and clinical use cases. Understanding these differences, rather than treating “cannabis” as one substance, is central to using it safely and effectively.

Cannabis is often reduced to “THC gets you high, CBD helps you relax.” That shorthand misses most of the picture. The plant produces over 100 known cannabinoids, and several beyond the two familiar ones, CBG, CBN, and THCV among them, have distinct pharmacology and emerging clinical relevance.

CBN may support sleep without the grogginess some patients report with THC alone. CBG is being studied for focus and gastrointestinal comfort. THCV is of particular interest in metabolic and appetite research. Each is worth understanding on its own terms rather than lumping into a single “cannabis” category.

THC (tetrahydrocannabinol) is the cannabinoid responsible for intoxication. It binds strongly to CB1 receptors in brain regions governing mood, sensory processing, and reward, which is why it can alter perception, appetite, and pain signaling. THC remains the most clinically studied cannabinoid, with evidence supporting its use for chronic pain, chemotherapy-associated nausea, appetite stimulation, and spasticity, alongside a well-documented risk profile that includes anxiety, tachycardia, and, in rare cases, cannabinoid hyperemesis syndrome.

• Patients with chronic pain, nausea, or appetite loss
• Those seeking fast symptom relief who tolerate psychoactivity well
• Use under physician guidance given its regulatory and side-effect profile

• Whiting PF, et al. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis. JAMA. 2015;313(24):2456–2473. DOI: 10.1001/jama.2015.6358
• Abrams DI, et al. Cannabis in painful HIV-associated sensory neuropathy. Neurology. 2007;68(7):515–521. DOI: 10.1212/01.wnl.0000253187.66183.9c

CBD (cannabidiol) does not bind strongly to CB1 or CB2 receptors; instead it modulates them and interacts with serotonin (5-HT1A) and GABA pathways relevant to mood and anxiety. Clinical interest centers on anxiety disorders, inflammation, and epilepsy, where CBD (as Epidiolex) holds FDA approval for Dravet and Lennox-Gastaut syndromes. CBD does not reliably produce sedation on its own; effects are dose-dependent and often subtle.

• Patients with anxiety, inflammation, or epilepsy
• THC-sensitive individuals seeking therapeutic effect without intoxication

• Shannon S, et al. Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm J. 2019;23. PMC6326553
• Devinsky O, et al. Trial of Cannabidiol for Drug-Resistant Seizures in Dravet Syndrome. N Engl J Med. 2017;376(21):2011–2020. DOI: 10.1056/NEJMoa1611618

CBG (cannabigerol) is the chemical precursor to THC, CBD, and other cannabinoids, existing in the raw plant as CBGA before enzymatic conversion. Preserved through early harvest or cultivar selection, CBG interacts with alpha-2 adrenergic receptors and TRPV1/TRPA1 channels. Early evidence points to potential roles in inflammatory bowel disease, neuroprotection, and mood regulation, though it remains understudied relative to THC and CBD.

• Patients exploring options for GI inflammation or daytime focus
• Those wanting calm without sedation

• Borrelli F, et al. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol. 2013;85(9):1306–1316. DOI: 10.1016/j.bcp.2013.01.017
• Valdeolivas S, et al. Neuroprotective properties of cannabigerol in Huntington’s disease. Neurotherapeutics. 2015;12(2):426–438. DOI: 10.1007/s13311-014-0337-3

CBN (cannabinol) is a degradation product of THC formed through exposure to air, heat, or light, which is why aged cannabis often contains more of it. Emerging research suggests the sedative effect commonly attributed to CBN may actually come from the broader mix of oxidized byproducts that accompany it, particularly when combined with THC and sleep-associated terpenes like myrcene and linalool, rather than from CBN in isolation.

• Patients experimenting with cannabis for insomnia
• Those seeking a gentler nighttime option than high-THC products

• Karniol IG, et al. Effects of cannabinol alone and in combination with delta9-tetrahydrocannabinol in man. Psychopharmacologia. 1975;42(4):329–338. DOI: 10.1007/BF00496910
• Cox S, et al. Cannabinol exhibits anti-convulsant activity in a mouse model of generalized seizure. Neuropharmacology. 2019;148:130–136. DOI: 10.1016/j.neuropharm.2018.12.002

THCV (tetrahydrocannabivarin) is structurally similar to THC but behaves as a CB1 receptor antagonist at lower doses, producing a clear-headed, non-euphoric, appetite-suppressing effect rather than a classic high. Animal studies show reduced body fat gain and improved insulin sensitivity, and small human trials have examined its effect on fasting glucose in type 2 diabetes. At higher doses THCV can begin to behave more like THC, so dose and product purity matter.

• Patients interested in metabolic health or appetite regulation
• Daytime use where THC’s psychoactivity is undesirable

• Wargent ET, et al. The cannabinoid Δ9-THCV has anti-obesity and glucose normalizing effects in animal models of obesity. Br J Pharmacol. 2013;170(3):656–672. DOI: 10.1111/bph.12273
• Englund A, et al. The effect of five-day THCV treatment on fasting plasma glucose and insulin levels in type 2 diabetes patients. Diabetes Care. 2016;39(10):1777–1786. DOI: 10.2337/dc16-0650
• Rock EM, et al. Evaluation of the potential of the phytocannabinoid THCV in epilepsy models. Epilepsia. 2021;62(1):120–130. DOI: 10.1111/epi.16760

No single cannabinoid is universally “best.” The right choice depends on the symptom being addressed, THC sensitivity, and whether daytime function or nighttime rest is the goal. Combination products, reflecting the entourage effect, often outperform any single isolated cannabinoid, which is why product labeling and third-party lab testing matter as much as the cannabinoid name on the package.

This article is educational and not a substitute for individualized medical advice. Cannabinoid effects vary by dose, formulation, and individual physiology; discuss any new regimen with a cannabis-literate clinician.

What’s the difference between THC and CBD?

THC is psychoactive and produces intoxication; CBD is non-intoxicating and is more often used for anxiety, inflammation, and seizure support. They interact with different receptor systems in the body.

Is CBG the same as CBD?

No. CBG (cannabigerol) is a distinct cannabinoid, often described as more energizing, and it is the biochemical precursor to THC and CBD in the raw plant.

Does CBN actually help with sleep?

CBN alone is mildly sedating. Its sleep-related reputation appears to depend heavily on being combined with THC and specific terpenes rather than acting alone.

What does THCV do?

THCV may suppress appetite, increase alertness, and help stabilize blood sugar. It is being studied for metabolic and neurological applications.

Are minor cannabinoids like CBG, CBN, and THCV legal?

Many hemp-derived minor cannabinoids are federally legal in the U.S. under the 2018 Farm Bill, though state law and product-specific regulation vary.

Which cannabinoid is best for pain?

THC remains the most extensively studied cannabinoid for pain, particularly when combined with CBD. CBG and CBN may contribute anti-inflammatory effects in some contexts.

Can cannabinoids be combined safely?

Yes. The entourage effect describes how cannabinoids and terpenes often work better in combination than in isolation, though individual response varies and should be guided by a clinician.

Is THCV safe for people with anxiety?

In low doses THCV may support focus and energy, but higher doses can occasionally trigger anxiety in sensitive individuals. Starting low and consulting a cannabis-literate clinician is advised.

Is CBG stimulating like caffeine?

CBG is not a stimulant, but many patients describe its effect as clarifying or alerting, making it a common daytime alternative to more sedating cannabinoids.

What’s the best cannabinoid to start with?

CBD is generally considered the safest entry point. Patients seeking therapeutic effect often begin with a low-dose THC:CBD combination under physician guidance.